LEADER 01298nam  2200361Ia 450 
001 9910696963303321
005 20230902162114.0
035   $a(CKB)5470000002383258
035   $a(OCoLC)540607620
035   $a(EXLCZ)995470000002383258
100   $a20100305d2008      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry and review staff$b[electronic resource] $enonclinical safety evaluation of reformulated drug products and products intended for administration by an alternate route
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2008]
215   $a1 electronic resource (8 pages)
300   $a"Draft guidance."
300   $a"Pharmacology/Toxicology."
300   $a"March 2008."
517   $aGuidance for industry and review staff 
606   $aDrugs$zUnited States$xTesting
615  0$aDrugs$xTesting.
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910696963303321
996   $aGuidance for industry and review staff$93444689
997   $aUNINA